Fennec Pharmaceuticals, Inc. (FENC)
11.74
+0.34
(+2.98%)
USD |
NASDAQ |
Aug 25, 16:00
11.74
0.00 (0.00%)
After-Hours: 19:59
Fennec Pharmaceuticals Enterprise Value : 358.14M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 358.14M |
| August 21, 2026 | 354.28M |
| August 20, 2026 | 356.39M |
| August 19, 2026 | 374.60M |
| August 18, 2026 | 374.60M |
| August 17, 2026 | 373.20M |
| August 14, 2026 | 369.35M |
| August 13, 2026 | 381.26M |
| August 12, 2026 | 373.20M |
| August 11, 2026 | 406.49M |
| August 10, 2026 | 342.02M |
| August 07, 2026 | 364.27M |
| August 06, 2026 | 338.52M |
| August 05, 2026 | 327.31M |
| August 04, 2026 | 312.94M |
| August 03, 2026 | 294.73M |
| July 31, 2026 | 294.03M |
| July 30, 2026 | 305.94M |
| July 29, 2026 | 296.83M |
| July 28, 2026 | 306.99M |
| July 27, 2026 | 316.45M |
| July 24, 2026 | 308.74M |
| July 23, 2026 | 314.35M |
| July 22, 2026 | 320.30M |
| July 21, 2026 | 322.75M |
| Date | Value |
|---|---|
| July 20, 2026 | 305.59M |
| July 17, 2026 | 326.61M |
| July 16, 2026 | 324.51M |
| July 15, 2026 | 330.11M |
| July 14, 2026 | 349.73M |
| July 13, 2026 | 335.37M |
| July 10, 2026 | 326.26M |
| July 09, 2026 | 319.95M |
| July 08, 2026 | 317.85M |
| July 07, 2026 | 326.61M |
| July 06, 2026 | 333.26M |
| July 02, 2026 | 333.61M |
| July 01, 2026 | 321.00M |
| June 30, 2026 | 335.37M |
| June 29, 2026 | 340.81M |
| June 26, 2026 | 340.46M |
| June 25, 2026 | 324.23M |
| June 24, 2026 | 319.05M |
| June 23, 2026 | 315.59M |
| June 22, 2026 | 289.00M |
| June 18, 2026 | 272.76M |
| June 17, 2026 | 270.00M |
| June 16, 2026 | 269.31M |
| June 15, 2026 | 277.25M |
| June 12, 2026 | 270.69M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Abeona Therapeutics, Inc. | 219.84M |
| ACADIA Pharmaceuticals, Inc. | 4.221B |
| Alnylam Pharmaceuticals, Inc. | 31.24B |
| Anika Therapeutics, Inc. | 272.43M |
| Savara, Inc. | 999.39M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.973M |
| Revenue (Quarterly) | 17.87M |
| Total Expenses (Quarterly) | 15.90M |
| EPS Diluted (Quarterly) | 0.0542 |
| Gross Profit Margin (Quarterly) | 95.97% |
| Profit Margin (Quarterly) | 11.04% |
| Earnings Yield | -1.09% |
| Normalized Earnings Yield | -0.7044 |